5 Most Promising Psychedelic Stocks According to Hedge Funds

2. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Number of Hedge Fund Investors In Q3 2023: 37

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) focuses on treatments for central nervous system disorders such as depression and schizophrenia. The firm posted strong earnings results for its third quarter in October, when it shared that revenue had grown to $126 million compared to the year ago figures of $71 million.

By the end of this year’s third quarter, 37 out of the 910 hedge funds part of Insider Monkey’s research had invested in the company. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s biggest hedge fund investor is David Kroin’s Deep Track Capital through its $135 million stake.

Follow Intra-Cellular Therapies Inc. (NASDAQ:ITCI)